Navigation Links
Use of Anti-Depressant Does not Help Patients with Anorexia Nervosa

CHICAGO - Use of the anti-depressant fluoxetine did not help patients with anorexia nervosa who had restored their body weight maintain// that weight or reduce their risk of relapse, according to a study in the June 14 issue of JAMA.

Anorexia nervosa is an eating disorder primarily affecting young women and marked by an extreme fear of becoming overweight that leads to excessive dieting to the point of serious ill-health and sometimes death. It is a serious psychiatric illness with a lifetime death rate arguably as high as that associated with any psychiatric illness, according to background information in the article. A major contributor to the poor prognosis of this illness is the high rate of relapse, with 30 to 50 percent of patients requiring rehospitalization within 1 year of discharge after successful weight restoration. This has prompted interest in interventions aimed at preventing relapse following weight restoration. A substantial number of patients with anorexia nervosa receive antidepressant medications. Fluoxetine was initially marketed under the brand name of Prozac.

B. Timothy Walsh, M.D., of New York State Psychiatric Institute/Columbia University Medical Center, New York, and colleagues compared fluoxetine with placebo to determine the rate of relapse and behavioral recovery following initial treatment for anorexia nervosa. The trial included 93 patients with anorexia nervosa who had received intensive inpatient or day-program treatment and regained weight to a minimum body mass index (BMI) of 19.0. Participants were then randomly assigned to receive fluoxetine (n = 49) or placebo (n = 44) and were treated for up to 1 year as outpatients.

The researchers found that similar percentages of patients assigned to fluoxetine and to placebo maintained a BMI of at least 18.5 and remained in the study for 52 weeks (fluoxetine: 26.5 percent; placebo: 31.5 percent). The most conservative analysis of time-to-relapse found no sign ificant difference between the fluoxetine and placebo groups in time-to-relapse. At 52 weeks, 45 percent of the placebo group and 43 percent of the fluoxetine group had not relapsed.

"The current study has implications for both clinical practice and research. The present findings, coupled with those of previously published studies, indicate that the common practice of prescribing antidepressant medication is unlikely to provide substantial benefit for most patients with anorexia nervosa, either when they are underweight or immediately upon weight restoration. These data imply that therapeutic efforts would be better devoted to psychological and behavioral interventions for which there is some, albeit modest, evidence of efficacy," the authors write. "Future research on the utility of novel psychological treatments and innovative psychotropic and nonpsychotropic medications is obviously needed."


'"/>




Related medicine news :

1. Skeleton May Sustain Damage Due To Use Of Anti-Depressants
2. Risk Of Birth Defects Increased Due To Anti-Depressant Medication
3. Low Doses of Anti-Depressant May Help PMS
4. One in Three Heart Attack Patients Have No Chest Pains
5. Amphetamines Help Recovery of Stroke Patients
6. Painkillers Do Not Shorten Dying Patients Lives
7. Patients With Filariasis More Prone To HIV Infection
8. Glivec - New Hope For CMC Patients
9. Patients often assume wrongly that they are allergic to penicillin
10. New FDA Approved Drug NATRECOR For Heart Failure Patients
11. Hemochromatosis Patients Blood is Safe
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... ANN ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, ... ... (PRWEB) January 18, 2017 -- Global public ... pitcher to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: ... Standard for drinking water treatment units. This certification verifies that ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed ... in central Maryland and the DC region, is inaugurating a charity event aimed at ... every year, making it the #1 killer in America. However, heart disease is largely ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. ... website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President ... the field of biosimilars through thought leader interaction in, live video and interactive ...
(Date:1/17/2017)... ... 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now in its ... corners and commit the crime of stalking, a very real danger to many in our ... factor in stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, ... Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, ... endure and pass through tough times, Dr. Bernie Siegel energizes listeners to live ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
Breaking Medicine Technology: